Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1100
Registration Number
NCT06632327

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

First Posted Date
2024-10-09
Last Posted Date
2024-12-20
Lead Sponsor
AbbVie
Target Recruit Count
150
Registration Number
NCT06632951
Locations
🇺🇸

Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

First Posted Date
2024-10-07
Last Posted Date
2024-10-07
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
400
Registration Number
NCT06629597
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

First Posted Date
2024-10-01
Last Posted Date
2024-12-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT06618014
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

First Posted Date
2024-09-27
Last Posted Date
2024-09-27
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
378
Registration Number
NCT06616584

Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People With Metastatic Castration Sensitive Prostate Cancer and Less Than Optimal PSA Response

First Posted Date
2024-09-19
Last Posted Date
2024-10-21
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
830
Registration Number
NCT06592924

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

First Posted Date
2024-08-29
Last Posted Date
2024-08-29
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
29
Registration Number
NCT06576635

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

First Posted Date
2024-08-13
Last Posted Date
2024-11-18
Lead Sponsor
Pfizer
Target Recruit Count
600
Registration Number
NCT06551324
Locations
🇨🇳

Tongji Hospital of Tongji University, Shanghai, Shanghai, China

🇯🇵

Keio university hospital, Shinjuku-ku, Tokyo, Japan

🇰🇷

Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of

and more 22 locations

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

First Posted Date
2024-08-09
Last Posted Date
2024-11-14
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT06545955
Locations
🇺🇸

Ferring Investigational Site, Los Angeles, California, United States

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
42
Registration Number
NCT06542731
Locations
🇯🇵

National Cancer Center Hospital, Chuo Ku, Tokyo, Japan

🇯🇵

The Cancer Institute Hospital of JFCR, Koto-ku, Japan

🇯🇵

Teikyo University Hospital, Itabashi-ku, Japan

and more 10 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy